Hagop M. Kantarjian

TL;DR: It is suggested that intermediate dose rates, 200 to 250 mg/m2/h, should be evaluated in future studies as an alternative to the substantially higher ara-C dose rates currently in use and support the conclusion that high-dose aRA-C therapy, as currently administered, results in plasma aarabinofuranosylcytosine concentrations that saturate the accumulation of aa-CTP by circulating leukemic cells.

TL;DR: The availability of very sensitive techniques for detection of the Philadelphia chromosome at the molecular level has allowed the detection of minimal residual disease in CML, and the alternatives for patients with accelerated and blastic phase CML are discussed.

TL;DR: These results demonstrate that under proper conditions, treatment discontinuation is feasible outside of clinical trial setting and are associated with very low risk of loss of MR4.5.

TL;DR: The authors' data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations, whereas initially high-risk patients demonstrate decreasing risk over time, and should be considered in clinical decision making.